Menu
← Oncology Approval Tracker
FDA DECISION ·
Besremi
ropeginterferon alfa-2b-njft · PharmaEssentia
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with essential thrombocythemia.
LAMPGEN ANALYSIS
Why it matters
The indication extends a long-acting interferon to a second myeloproliferative neoplasm. The FDA-reviewed study compared it with anagrelide after resistance or intolerance to hydroxyurea.
What research teams should watch
Track prior cytoreductive therapy and longitudinal blood counts. Separate the approved indication from the prior-treatment population enrolled in SURPASS ET.
PRIMARY RECORDS